Your browser doesn't support javascript.
loading
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 929-936, 2014.
Article in English | WPRIM | ID: wpr-253231
Responsible library: WPRO
ABSTRACT
<p><b>BACKGROUND</b>Prostate specific membrane antigen (PSMA) can facilitate the growth, migration, and invasion of the LNCaP prostate cancer cell lines, but the underlying molecular mechanisms have not yet been clearly defined. Here, we investigated whether PSMA serves as a novel regulator of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling by employing PSMA knockdown model and PI3K pharmacological inhibitor (LY294002) in LNCaP prostate cancer cells.</p><p><b>METHODS</b>PSMA knockdown had been stably established by transfecting with lentivirus-mediated siRNA in our previous study. Then, LNCaP cells were divided into interference, non-interference, and blank groups. We first testified the efficacy of PSMA knockdown in our LNCaP cell line. Then, we compared the expression of PSMA and total/activated Akt by Western blotting in the above three groups with or without LY294002 treatment. Furthermore, immunocytochemistry was performed to confirm the changes of activated Akt (p-Akt, Ser473) in groups. Besides, cell proliferation, migration, and cell cycle were measured by CCK-8 assay, Transwell analysis, and Flow cytometry respectively.</p><p><b>RESULTS</b>After PSMA knockdown, the level of p-Akt (Ser473) but not of total-Akt (Akt1/2) was significantly decreased when compared with the non-interference and blank groups. However, LY294002 administration significantly reduced the expression of p-Akt (Ser473) in all the three groups. The results of immunocytochemistry further confirmed that PSMA knockdown or LY294002 treatment was associated with p-Akt (Ser473) down-regulation. Decrease of cell proliferation, migration, and survival were also observed upon PSMA knockdown and LY294002 treatment.</p><p><b>CONCLUSIONS</b>Taken together, our results reveal that PI3K/Akt signaling pathway inhibition may serve as a novel molecular mechanism in LNCaP prostate cancer cells of PSMA knockdown and suggest that Akt (Ser473) may play a critical role as a downstream signaling target effector of PSMA in this cellular model.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Physiology / Prostatic Neoplasms / Therapeutics / Humans / Male / Signal Transduction / Phosphatidylinositol 3-Kinases / RNA Interference / Cell Line, Tumor / Glutamate Carboxypeptidase II Language: English Journal: Chinese Medical Journal Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Physiology / Prostatic Neoplasms / Therapeutics / Humans / Male / Signal Transduction / Phosphatidylinositol 3-Kinases / RNA Interference / Cell Line, Tumor / Glutamate Carboxypeptidase II Language: English Journal: Chinese Medical Journal Year: 2014 Type: Article